In the BioHarmony Drug Report Database

"Preview" Icon

Voxelotor

Oxbryta (voxelotor) is a small molecule pharmaceutical. Voxelotor was first approved as Oxbryta on 2019-11-25. It is used to treat sickle cell anemia in the USA. It is known to target cytochrome P450 2C8, cytochrome P450 3A4, and cytochrome P450 2C9. Oxbryta’s patents are valid until 2037-10-12 (FDA).

 

Trade Name

 

Oxbryta
 

Common Name

 

voxelotor
 

ChEMBL ID

 

CHEMBL4101807
 

Indication

 

sickle cell anemia
 

Drug Class

 

Image (chem structure or protein)

Voxelotor structure rendering